Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Megestrol acetate + olanzapine is a combination therapy used primarily for the treatment of cancer-related anorexia (CRA) and weight loss in patients with advanced cancer. Megestrol acetate is a synthetic progesterone derivative that may work by affecting certain hormones to slow the growth of certain tissues and increase appetite. Olanzapine is an atypical antipsychotic that has shown effectiveness in stimulating appetite and reducing nausea. The combination has demonstrated superior efficacy compared to megestrol acetate alone in improving weight gain, appetite, nausea, and quality of life measures in patients with advanced cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on megestrol acetate + olanzapine.